Immunosuppressive therapy in lung transplantation: state of the art

European Journal of Cardio-thoracic Surgery

Volumn 35, Issue 6, 2009, Pages 1045-1055

  Korom, Stephan ^a   Boehler, Annette ^a   Weder, Walter ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Immunosuppression; Lung transplantation; State of the art

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN A; DACLIZUMAB; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; OKT 3; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

CLINICAL TRIAL; DRUG MECHANISM; EVIDENCE BASED PRACTICE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ANTIMETABOLITES; CALCINEURIN; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LUNG TRANSPLANTATION; SIROLIMUS;

EID: 67349222178     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcts.2009.02.035     Document Type: Review

References (100)

1. McGowan S.E., and Snyder S.M. Development of alveoli. In: Harding R., Pinkerton K.E., and Plopper C.G. (Eds). The lung. Development, aging and the environment (2004), Elsevier Academic Press, San Diego 55-73
2. Taylor D.O., Edwards L.B., Aurora P., Christie J., Dobbels F., Kirk R., Rahmel A.O., Kucheryavaya A.Y., and Hertz M.I. Registry of the international society of heart and lung transplantation: twenty-fourth official adult heart transplant report - 2008. J Heart Lung Transplant 27 (2008) 7943-7956
3. Christie J., Edwards L.B., Aurora P., Dobbels F., Kirk R., Rahmel A.O., Taylor D.O., Kucheryavaya A.Y., and Hertz M.I. Registry of the international society for heart and lung transplantation: twenty-fifth official adult lung and heart/lung transplant report - 2008. JHLT 27 (2007) 957-969
4. Chan M., and Pearson G.J. New advances in antirejection therapy. Curr Opin Cardiol 22 (2007) 117-122
5. Bonnefoy-Berard N., and Revillard J.P. Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3. J Heart Lung Transplant 15 (1994) 435-442
6. Lindenfeld J., Page R.L., Zolty R., Shakar S.F., Levi M., Lowes B.D., Wolfel E.E., and Miller G.G. Drug therapy in the heart transplant recipient: part III: common medical problems. Circulation 111 (2005) 113-117
7. Palmer S., Miralles A.P., Lawrence C.M., Gaynor J.W., Davis R.D., and Tapson V.F. Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. Chest 116 (1999) 127-133
8. Chatenoud L., Ferran C., Reuter A., Legendre C., Gevaert Y., Kreis H., Franchimont P., and Bach J.P. Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma. N Engl J Med 320 (1989) 1420-1421
9. Brock M.V., Borja M.C., Ferber L., Orens J.B., Anzcek R.A., Krishnan J., Yang S.C., and Conte J.V. Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti-thymocyte globulin, and daclizumab. J Heart Lung Transplant 20 (2001) 1282-1290
10. Borro J.M., De la Torre M., Miguelez R., Fernandez R., Gonzalez D., and Lemos C. Comparative study of basiliximab treatment in lung transplantation. Transplant Proceed 37 (2005) 3996-3998
11. Mullen J., Oeropoulos A., Lien D.C., Bentley M.J., Modry D.L., Stewart K., Winton T.L., Jackson K., Doucette K., Preiksaitis J., and Halloran P. A randomized, controlled trial of daclizumab vs anti-thymocyte globulin induction for lung transplantation. J Heart Lung Transplant 26 (2005) 504-510
12. Lischke R., Simonek J., Davidova R., Schützner J., Stolz A.J., Vojacek J., Burkert J., and Pafko P. Induction therapy in lung transplantation: initial single-center experience comparing daclizumab and antithymocyte globulin. Transplant Proc 39 (2007) 205-212
13. Hachem R.R., Chakinala M.M., Yusen R.D., Lynch J.P., Aloush A.A., Patterson G.A., and Trulock E.P. A comparison of basiliximab and anti-thymocyte globulin induction agents after lung transplantation. J Heart Lung Transplant 24 (2004) 1320-1326
14. Burton C., Andersen C.B., Jensen A.S., Iversen M., Milman N., Boesgaard S., Arendrup H., Eliasen K., and Carlsen J. The incidence of acute cellular rejection after lung transplantation: a comparative study of anti-thymocyte globulin and daclizumab. J Heart Lung Transplant 25 (2006) 638-647
15. Ailawadi G., Smith P.W., Tomomi O., Wang H., Kozower B.D., Daniel T.M., Kron I.L., and Jones D.R. Effects of induction immunosuppression regimen on acute rejection, bronchiolitis obliterans, and survival after lung transplantation. J Thorac Cardiovasc Surg 136 (2008) 594-602
16. Hachem R., Edwards L.B., Yousen R.D., Chakinala M.M., Patterson G.A., and Trulock EP. The impact of induction on survival after lung transplantation: an analysis of the international society for heart and lung transplantation registry. Clin Transplant 22 (2008) 603-608 [Epub ahead of print]
17. Mc Curry K.R., Iacono A., Zeevi A., Yousem S., Girnita A., Husain S., Zaldonis D., Johnson B., Hattler B.G., and Starzl T.E. Early outcomes in human lung transplantation with thymoglobulin or campath-1H for recipient pretreatment followed by post transplant tacrolimus near-monotherapy. JTCS 130 (2005) 528-537
18. Levine S.M. A survey of clinical practice of lung transplantation in north America. Chest 125 (2004) 1224-1238
19. Shitrit D., Bendayan D., Sulkes J., Bar-Gil Shitrit A., Huerta M., and Kramer M.R. Successful steroid withdrawal in lung transplant recipients: result of a pilot study. Respir Med 99 (2005) 596-601
20. Borro J.M., Sole A., De la Torre M., Pastor A., and Torazona V. Steroid withdrawal in lung transplant recipients. Transplant Proceed 37 (2005) 3991-3993
21. Reitz B., Wallwork J.L., Hunt S.A., Pennock J.L., Billingham M.E., Oyer P.E., Stinson E.B., and Shumway N.E. Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease. N Engl J Med 306 (1982) 557-564
22. Briffa N., and Morris R. New immunosuppressive regimens in lung transplantation. Eur Respir J 10 (1997) 2630-2637
23. Kahan B., Dunn J., Fitts C., Van Buren D., Womboldt D., Pollak R., Carson R., Alexander J.W., Choc M., Wong R., and Hwang D.S. Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals. Transplantation 27 (1995) 505-511
24. Trull A., Steel L., Sharples L., Sterwart S., Parameshwar J., McNeil K., and Wallwork J. Randomized, trough blood cyclosporine concentration-controlled trial to compare the pharmacodynamics of sandimmune and neoral in de novo lung transplant recipients. Drug Monit 21 (1999) 17-26
25. Glanville A.R., Abouyoun C.L., Morton J.M., Plitt M., and Malouf M.A. Cyclosporine C2 target levels and acute cellular rejection after lung transplantation. J Heart Lung Transplant 25 (2006) 928-934
26. Iacono A., Johnson B.A., Grgurich W.F., Youssef J.G., Corcoran T.E., Seiler D.A., Dauber J.H., Smaldone G.C., Zeevi A., Yousem S.A., Fung J.J., Burckart G.J., McCurry K.R., and Griffith B.P. A randomized trial of inhaled cyclosporine in lung-transplant recipients. N Engl J Med 12 (2006) 141-150
27. Galazka M., Groves T., Corcoran T., Johnson B., Suffredini A., Britt E., Sherman B., Augustine S., Moainie S., Todd N., Griffith B., and Iacono A. Preservation of pulmonary function by inhaled cyclosporine in lung transplant recipients. J Heart Lung Transplant 27 2S (2008) S206
28. Schreiber S., Liu J., Albers M.W., Karmacharya R., Koh E., Martin P.K., Rosen M.K., Standeart R.F., and Wandless T.J. Immunophillin-ligand complexes as probes of intracellular signaling pathways. Transplant Proc 23 (1991) 2839-2844
29. First R. First clinical experience with the new once-daily formulation of tacrolimus. Ther Drug Monit 30 (2008) 159-166
30. Keenan R., Iacono A., and Dauber J.H. Clinical trial of tacrolimus versus cyclosporine in lung transplantation. Ann Thorac Surg 60 (1995) 580-585
31. Zuckermann A., Reichenspurner H., Birsan T., Treede H., Deviatko E., Reichart B., and Klepetko W. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one year results of a 2-center prospective randomized trial. J Thorac Cardiovasc Surg 125 (2003) 891-900
32. Reichenspurner H., Glanville A.R., Christina A., Lama R., Carlos B., Marc E., Aubert J.D., Treede H., and Klepetko W. Complete 3 year analysis of a prospective randomized international multi-center investigator driven study comparing tacrolimus and cyclosporin A, both in combination with MMF and steroids after lung transplantation in 249 patients. J Heart Lung Transplant 27 (2008) S205-S206
33. Murray J.E., Merril J.P., Harrison J.H., Wilson R.E., and Dammin G.J. Prolonged survival of human kidney homografts by immunosuppressive drug therapy. N Engl J Med 268 (1963) 1315-1323
34. Elion G.B. The purine path to chemotherapy. Science 244 (1989) 41-47
35. Cooper J.D., Pearson F.G., Patterson G.A., Todd T.R., Ginsberg R.J., Goldberg M., and DeMajo W.A. Technique of successful lung transplantation in humans. J Thorac Cardiovasc Surg 93 (1987) 173-181
36. Morris R., Hoyt E.G., Eugui E.M., and Allison A.C. Prolongation of heart allograft survival by RS 61443. Surg Forum 40 (1989) 337
37. Sollinger H., Deierhoi M.H., Belzer F.O., Diethelm A.G., and Kauffmann R.S. RS-61443 - a phase I clinical trial and pilot rescue study. Transplantation 53 (1992) 428-432
38. Knoop C., Haverich A., and Fischer S. Immunosuppressive therapy after human lung transplantation. Eur Respir J 23 (2004) 159-171
39. Sollinger H. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. renal transplant mycophenolate mofetil study group. Transplantation 60 (1995) 225-232
40. Kobashigawa J., Miller L., Renlund D., Mentzer R., Aldeman E., Bourge R., Costanzo M., Eisen H., Dureau G., Ratkovec R., Hummel M., Ipe D., Johnson J., Keogh A., Mamelok R., Mancini D., Smart F., and Valantine H. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate mofetil investigators. Transplantation 27 (1998) 507-515
41. O'Hair D., Cantu E., McGregor C., Jorgensen B., Gerow-Smith R., Galantowicz M.E., and Schulman L.L. Preliminary experience with mycophenolate mofetil used in lung transplantation. J Heart Lung Transplant 17 (1998) 864-868
42. Ross D., Waters P.F., Levine M., Kramer M., Ruzevich S., and Kass R.M. Mycophenolate mofetil versus azathioprine immunosuppressive regimens after lung transplantation: preliminary experience. J Heart Lung Transplant 17 (1998) 768-774
43. Zuckermann A., Klepetko W., Birsan T., Taghavi S., Artemiou O., Wisser W., Dekan G., and Wolner E. Comparison between mycophenolate mofetil- and azathioprine-based immunosuppression in clinical lung transplantation. J Heart Lung Transplant 18 (1999) 432-440
44. Speich R., Boehler A., Zalunardo M.P., Stocker R., Russi E., and Weder W. Improved results after lung transplantation - analysis of factors. Swiss Med Wkly 131 (2000) 238-245
45. Palmer S., Baz M.A., Sanders L., Miralles A.P., Lawarence C.M., Rea J.B., Zander D.S., Edwards L.J., Staples E.D., Tapson V.F., and Davis R.D. Results of a randomized, prospective multicenter trial of mycophenolate mofetil versus azathioprine in the prevention of acute lung allograft rejection. Transplantation 71 (2001) 1772-1776
46. McNeil K., Glanville A.R., Wahlers T., Knoop C., Speich R., Mamelok R.D., Maurer J., Ives J., and Corrsi P.A. Comparison of mycophenolate mofetil and azathioprine for prevention of bronchiolitis obliterans syndrome in de novo lung transplant recipients. Transplantation 81 (2006) 998-1003
47. van Gelder T., Klupp J., Barten M.J., Christians U., and Morris R.E. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 23 (2001) 119-128
48. Gerbase M.W., Fathi M., Spiliopoulos A., Rochat T., and Nicod L.P. Pharmacokinetics of mycophenolic acid associated with calcineurin inhibitors: long-term monitoring in stable lung recipients with and without cystic fibrosis. J Heart Lung Transplant 22 (2003) 587-590
49. Knight S., and Morris P.J. Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic review. Transplantation 85 (2008) 1675-1685
50. Budde K., Glander P., Diekmann F., Waiser J., Fritsche L., Dragun D., and Neumayer H.H. Review of the immunosuppressant enteric-coated mycophenolate sodium. Expert Opin Pharmacother 5 (2004) 1333-1345
51. Salvadori M., Holzer H., De Mattos A., Sollinger H., Arns W., Oppenheimer F., Maca J., and Hall M. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 4 (2004) 231-236
52. Budde K., Curtis J., Knoll G., Chan L., Neumayer H.H., Seifu Y., and Hall M. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant 4 (2004) 237-247
53. Abraham R., and Wiederrecht G.J. Immunopharmacology of rapamycin. Annu Rev Immunol 14 (1996) 483-510
54. Bertagnolli M.M., Yang L., Hermann S.H., and Kirkman R.L. Evidence that rapamycin inhibits interleukin-12-induced proliferation of activated T lymphocytes. Transplantation 58 (1994) 1091-1096
55. Ternada N., Lucas J.J., Szepesi A., Franklin R.A., Domenico J., and Gelfand E.W. Rapamycin blocks cell cycle progression of activated T cells prior to events characteristic of the middle to late G1 phase of the cycle. J Cell Physiol 154 (1993) 7-15
56. Aagaard-Tillery K., and Jelinek D.F. Inhibition of human B lymphocyte cell cycle progression and differentiation by rapamycin. Cell Immunol 156 (1994) 493-507
57. Kim H., Raskova J., Degiannis D., and Raska Jr. K. Effects of cyclosporine and rapamycin on immunoglobulin production by preactivated human B cells. Clin Exp Immunol 96 (1994) 508-512
58. Cao W., Mohacsi P., Shorthouse R., Pratt R., and Morris R.E. Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis. Inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506. Transplantation 59 (1995) 390-395
59. Groetzner J., Wittwer T., Kaczmarek I., Ueberfuhr P., Strauch J., Nagib R., Meiser B., Franke U., Reichart B., and Wahler T. Conversion to sirolimus and mycophenolate can attenuate the progression of bronchiolitis obliterans syndrome and improves renal function after lung transplantation. Transplantation 81 (2006) 355-360
60. King-Biggs M., Dunitz J.M., Park S.J., Savik S.K., and Hertz M.I. Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation. Transplantation 75 (2003) 1437-1443
61. Groetzner J., Kur F., Spelsberg F., Behr J., Frey L., Bittmann I., Vogeser M., Ueberfuhr P., Meiser B., Hatz R., Reichart B., and Munich Lung Transplant Group. Airway anastomosis complications in de novo lung transplantation with sirolimus-based immunosuppression. J Heart Lung Transplant 23 (2004) 632-638
62. Kuppahally S., Al-Khaladi A., Weisshaar D., Valantine H.A., Oyer P., Robbins S.C., and Hunt S.A. Wound healing complications with de novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients. Am J Transplant 6 (2006) 986-992
63. Troppmann C., Pierce J.L., Gandhi M.M., Gallay B.J., McVicar J.P., and Perez R.V. Higher surgical wound complication rates with sirolimus immunosuppression after kidney transplantation: a matched-pair pilot study. Transplantation 76 (2003) 426-429
64. Guilbeau J. Delayed wound healing with sirolimus after liver transplant. Ann Pharmacother 36 (2002) 1391-1395
65. Ussetti P., Laporta R., de Pablo A., Carreno C., Segovia J., and Pulpon L. Rapamycin in lung transplantation: preliminary results. Transplant Proc 35 (2003) 1974-1977
66. Venuta F., De Giacomo T., Rendina E.A., Quattrucci S., Mercadante E., Cimino G., Ibrahim M., Diso D., Bachetoni A., and Coloni G.F. Recovery of chronic renal impairment with sirolimus after lung transplantation. Ann Thorac Surg 78 (2004) 1940-1943
67. Shitrit D., Rahamimov R., Gidon S., Bakal I., Bargil-Shitrit A., Milton S., and Kramer M.R. Use of sirolimus and low dose calcineurin inhibitor in lung transplant recipients with renal impairment: results of a controlled pilot study. Kid Int 67 (2006) 1471-1475
68. Villaneuva J., Boukhamseen A., and Bhorade S. Successful use in lung transplantation of an immunosuppressive regimen aimed at reducing target blood levels of sirolimus and tacrolimus. J Heart Lung Transplant 24 (2004) 421-425
69. Hernandez R., Ussetti P., Garcia Gallo C., de Pablo Gafas A., Carreno Hernandez M.C., and Ferreiro Alvarez M.J. Rapamycin in lung transplantation. Transplant Proc 37 (2005) 3999-4000
70. Bhorade S.M., Baz M., Ahya V., Seethamraju H., Valentine V., Charbeneau J., and Garrity E.R. Comparison of tacrolimus/sirolimus/prednisone regimen versus tacrolimus/azathioprine/prednisone immunosuppressive regimen in lung transplantation. J Heart Lung Transplant 27 (2008) S207
71. Pham P.T.T., Pham P.C.T., Danovitch G.M., Ross D.J., Gritsch H.A., Kendrick E.A., Singer J., Shah T., and Wilkinson A.H. Sirolimus-associated pulmonary toxicity. Transplantation 77 (2004) 1215-1220
72. McWilliams T., Bronwyn J.L., Russel P.A., Milne D.G., and Snell G.I. Interstitial pneumonitis associated with sirolimus: a dilemma for lung transplantation. J Heart Lung Transplant 22 (2003) 210-213
73. Antunez M.R., Parmar J., Hutcheon M.A., Chaparro C., Waddel T.K., Keshavjee S., and Singer L.G. Sirolimus-associated pneumonitis in lung transplant recipients. J Heart Lung Transplant 25 (2006) S170-171
74. Champion L., Stern M., Israel-Biet D., Mamzer-Bruneel M.F., Peraldi M.N., Kreis H., Porcher R., and Morelon E. Brief communication: sirolimus-associated pneumonitis: 24 cases in renal transplant recipients. Ann Intern Med 144 (2006) 505-509
75. Armstrong V.W., and Streit F. Drug monitoring of sirolimus and everolimus. Lab Medizin 27 (2003) 222-227
76. Kirchner G.I., Meier-Wiedenbach I., and Manns M.P. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 43 (2004) 83-95
77. Zuckermann A., Arizon J., Wang S.S., Maccherini M., Vermes E., Bara C., Ross H., Eisen H., Chapman J., and Valantine H. Impact of de novo everolimus based immunosuppression on wound healing and tissue regeneration in heart transplantation. J Heart Lung Transplant 27 (2008) S118
78. Exposito V., de Prada J.A., Gomez-Roman J.J., Gonzalez-Vilchez F., Llano-Cardenal M., García-Camarero T., Fernández-Valls M., Ruano J., and Martín-Durán R. Everolimus-related pulmonary toxicity in heart transplant recipients. J Heart Lung Transplant 27 (2008) 797-800
79. Rehm B., Keller F., Mayer J., and Stracke S. Resolution of sirolimus-induced pneumonitis after conversion to everolimus. Transplant Proc 38 (2006) 711-713
80. Snell G., Valentine V.G., Glanville A.R., McGiffin D.C., Loyd J.E., Roman A., Aris R., Sole A., Hmissi A., and Pirron U. Everolimus versus azathioprine in maintenance lung transplant recipients: an international, randomized, double-blind clinical trial. Am J Transplant 6 (2006) 169-177
81. Strueber M., Stefan F., Simon A.R., Warnecke G., Dietrich M., Haverich A., Welte T., and Gottlieb J. Everolimus versus mycophenolate mofetil in de novo immunosuppression after lung transplantation - interims analysis of a prospective, randomized, clinical trial. J Heart Lung Transplant 27 (2008) S205
82. Adcock I.M., and Ito K. Molecular mechanisms of corticosteroid actions. Monaldi Arch Chest Dis 55 (2000) 256-266
83. Stein E., Ebeling P., and Shane E. Post-transplantation osteoporosis. Endocrinol Metab Clin N Am 36 (2007) 937-963
84. Speich R., Boehler A., Russi E.W., and Weder W. A case-report of a double-blind, randomized trial of inhaled steroids in a patient with lung transplant bronchiolitis obliterans. Respiration 64 (1997) 375-380
85. Takao M., Hingenbottam T.W., Audley T., Otulana B.A., and Wallwork J. Effects of inhaled nebulized steroids (budesonide) on acute and chronic lung function in heart-lung transplant patients. Transplant Proc 27 (1995) 1284-1285
86. Whitford H., Walters E.H., Lewey B., Kotsimbos T., Orsida B., Ward C., Pais M., Reid S., Williams T., and Snell G. Addition of inhaled corticosteroids to systemic immunosuppression after lung transplantation: a double-blind, placebo-controlled trial. Transplantation 73 (2002) 1793-1799
87. Scott A.I., Sharples L., and Stewart S. Bronchiolitis obliterans syndrome: risk factors and therapeutic strategies. Drugs 65 (2005) 761-771
88. Shennib H., Mercado M., Nguyen D., Ernst P., Lebel F., O'Donnovan M., Fraser R., Tcherovenkov C., Morin J.F., and Mulder D. Successful treatment of steroid-resistant double-lung allograft rejection with orthoclone OKT1. Am Rev Respir Dis 144 (1991) 224-226
89. Keenan R., Iacono A., and Dauber J.H. Treatment of refractory acute allograft rejection with aerosolized cyclosporine in lung transplant recipients. J Thorac Cardiovasc Surg 21 (1997) 297-310
90. Cahill B.C., O'Rourke M.K., and Strasbourg K.A. Methotrexate for lung transplant recipients with steroid-resistant acute rejection. J Heart Lung Transplant 15 (1996) 1130-1137
91. Sarahrudi K., Estenne M., Corris P.A., Niedermayer J., Knoop C., Glanville A., Chaparro C., Verleden G., Gerbase M.W., Venuta F., Böttcher H., Aubert J.D., Lewey B., Reichenspurner H., Auterith A., and Klepetko W. International experience with conversion from cyclosporine to tacrolimus for acute and chronic lung allograft rejection. Thorac Cardiovasc Surg 127 (2004) 1126-1132
92. Astor T.L., and Weill D. Extracorporeal photopheresis in lung transplantation. J Cutan Med Surg 7 (2003) 20-24
93. Benden C., Speich R., Hofbauer G.F., Irani S., Eich-Wanger C., Russi E.W., Weder W., and Boehler A. Extracorporeal photopheresis after lung transplantation: a 10 year single-center experience. Transplantation 15 (2008) 1625-1627
94. D'Ovidio F., and Keshavjee S. Gastroesophageal reflux and lung transplantation. Dis Esophagus 19 (2006) 315-320
95. Dobbels F., Van Damme-Lombaert R., Vanhaecke J., and De Geest S. Growing pains: non-adherence with the immunosuppressive regimen in adolescent transplant recipients. Pediatr Transplant 9 (2005) 381-390
96. Snell I., Esmore D.S., and Williams T.J. Cytolytic therapy for the bronchiolitis obliterans syndrome complicating lung transplantation. Chest 109 (1996) 874-878
97. Cairn J., Yek T., Banner N.R., Khaghandi A., Hodson M.E., and Yacoub M. Time-related changes in pulmonary function after conversion to tacrolimus in bronchiolitis obliterans syndrome. J Heart Lung Transplant 22 (2003) 50-57
98. Fietta A., and Meloni F. Lung transplantation: the role of azithromycin in the management of patients with bronchiolitis obliterans syndrome. Curr Med Chem 15 (2008) 716-723
99. Trulock E.P., Edwards L.B., Taylor D.O., Boucek M.M., Mohacsi P.J., Keck B.M., and Hertz M.I. Registry of the international society for heart and lung transplantation: twentieth official adult lung and heart-lung transplantation report - 2003. J Heart Lung Transplant 22 (2003) 625-635
100. Treede H., Klepetko W., Reichenspurner H., Zuckermann A., Meiser B., Birsan T., Wisser W., and Reichart B. Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two-center trial comparing two different mmunosuppressive protocols. J Heart Lung Transplant 20 (2001) 511-517